阿比特龙与恩扎卢胺对心血管系统的不良反应不同:系统评价与网状Meta分析
该系统评价与网状Meta分析纳入7项RCT共7103例非转移性或转移性CRPC患者,比较阿比特龙与恩扎卢胺的心血管不良事件风险。成对Meta分析显示阿比特龙增加任何级别和严重级别心脏疾病风险,恩扎卢胺增加任何级别和严重级别高血压风险;SUCRA排序提示两者心血管风险谱不同,临床选择新型内分泌治疗药物时应加以考虑。
要点
- 阿比特龙与任何级别(RR=1.34)和严重级别(RR=1.71)心脏疾病风险升高相关。
- 恩扎卢胺与任何级别(RR=2.66)和严重级别(RR=2.79)高血压风险升高相关。
- SUCRA排序提示阿比特龙心脏疾病概率更高,恩扎卢胺高血压概率更高。
核心结论
- 阿比特龙和恩扎卢胺对心血管系统的不良反应不同,选择新型内分泌治疗药物时应考虑这一差异。
研究设计与样本
- 系统评价与成对及贝叶斯网状Meta分析,纳入7项II-IV期RCT共7103例非转移性或转移性CRPC患者。
主要发现
- 成对Meta分析显示阿比特龙与任何级别心脏疾病风险升高相关(RR=1.34,95%CI=1.05-1.73)。
- 阿比特龙与严重级别心脏疾病风险升高相关(RR=1.71,95%CI=1.16-2.53)。
- 恩扎卢胺与任何级别高血压风险升高相关(RR=2.66,95%CI=1.93-3.66)。
- 恩扎卢胺与严重级别高血压风险升高相关(RR=2.79,95%CI=1.86-4.18)。
- SUCRA排序:阿比特龙心脏疾病概率任何级别84.84%、严重级别85.12%,恩扎卢胺分别为62.83%和50.76%;恩扎卢胺高血压概率任何级别99.43%、严重级别89.71%,阿比特龙分别为49.08%和49.37%。
关键数值与推荐
- 结局指标包括任何级别心脏疾病、严重级别心脏疾病、任何级别高血压和严重级别高血压,均按CTCAE定义。
临床怎么用
- 对CRPC患者选择阿比特龙或恩扎卢胺时,应结合患者心血管基础疾病谱评估风险,阿比特龙侧重监测心脏疾病,恩扎卢胺侧重监测高血压。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Abiraterone and enzalutamide may increase the risk of cardiovascular events in patients with castration-resistant prostate cancer (CRPC). METHODS: A comprehensive literature search was performed using a combination of keywords related to "abiraterone," "enzalutamide," "prostate cancer," and "adverse events." Phase II-IV randomized controlled trials (RCTs) on abiraterone or enzalutamide for patients with nonmetastatic or metastatic CRPC were included. Outcome measures included (1) any grade cardiac disorder, (2) severe grade cardiac disorder, (3) any grade hypertension, and (4) severe grade hypertension, as defined by the Common Terminology Criteria for Adverse Events. Pairwise meta-analysis and Bayesian network meta-analyses were performed to investigate the risk ratios (RRs) of abiraterone and enzalutamide. Surface under cumulative ranking curves (SUCRAs) and cumulative ranking probability plots based on the probability of developing cardiac disorders or hypertension were presented. RESULTS: A total of 7103 patients from seven RCTs were included. Upon pairwise meta-analysis, abiraterone was associated with increased risks of any grade (RR = 1.34, 95% confidence interval (CI) = 1.05-1.73) and severe grade cardiac disorders (RR = 1.71, 95% CI = 1.16-2.53); enzalutamide was associated with increased risks of any grade (RR = 2.66, 95% CI = 1.93-3.66) and severe grade hypertension (RR = 2.79, 95% CI = 1.86-4.18). Based on the SUCRA rankings, abiraterone had a higher probability of cardiac disorders (84.84% for any grade and 85.12% for severe grade) than enzalutamide (62.83% for any grade and 50.76% for severe grade); whereas enzalutamide had a higher probability of hypertension (99.43% for any grade and 89.71% for severe grade) than abiraterone (49.08% for any grade and 49.37% for severe grade). CONCLUSIONS: Abiraterone and enzalutamide had different adverse effects on the cardiovascular system. We should take this into consideration when we are deciding on the choice of novel hormonal agents for patients with CRPC.
引用
- Lee HY, Chen HL, Teoh JY, et al. Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses. Prostate Cancer Prostatic Dis. 2020. PMID: 32860011. doi:10.1038/s41391-020-00275-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。